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Abstract.
Background: Data from an open label randomised controlled trial have suggested possible advantages on both motor and
non-motor measures in patients with Parkinson’s disease following 12 months exposure to exenatide.
Objective: Continued follow up of these same patients was performed to investigate whether these possible advantages persisted
in the prolonged absence of this medication.
Methods: All participants from an open label, randomised controlled trial of exenatide as a treatment for Parkinson’s disease,
were invited for a further follow up assessment at the UCL Institute of Neurology. This visit included all 20 individuals who
had previously completed twelve months exposure to exenatide 10ug bd and the 24 individuals who had acted as randomised
controls. Motor severity of PD was compared after overnight withdrawal of conventional PD medication using blinded video
assessment of the MDS-UPDRS, together with several non-motor tests. This assessment was thus 24 months after their original
baseline visit, i.e. 12 months after cessation of exenatide.
Results: Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points
(95% CI, 2.2–9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale. There was also a difference
of 5.3 points; (95% CI, 9.3–1.4; p = 0.006) between the 2 groups on the Mattis Dementia Rating scale.
Conclusions: While these data must still not be interpreted as evidence of neuroprotection, they nevertheless provide strong
encouragement for the further study of this drug as a potential disease modifying agent in Parkinson’s disease.
Keywords: Parkinson’s disease, clinical trial, disease modifying treatment, UPDRS, exenatide, diabetes mellitus
∗Correspondence to: Tom Foltynie, Box 146, National Hospital
for Neurology & Neurosurgery, Queen Square, WC1N 3BG, Lon-
don. Tel.: +44 (0) 203 448 8726; Fax: +44 (0) 203 448 0142; E-mail:
t.foltynie@ucl.ac.uk.
INTRODUCTION
Multiple avenues of research have identified links
between Parkinson’s disease (PD) and Type 2 dia-
betes mellitus (T2DM) [1]. Several recent discoveries
have highlighted common cellular pathways that
potentially relate neurodegenerative processes with
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abnormal mitochondrial function and abnormal glu-
cose metabolism [2]. In parallel with these advances,
a treatment for insulin resistance (exenatide; a GLP-1
agonist) has been proposed as a disease modifying drug
in PD, based on multiple in vitro and in vivo studies
[3–9].
In view of these preclinical data and in view of
the excellent safety profile in patients with T2DM,
a small, open-label “proof of concept” randomized
controlled trial was conducted at UCL Institute of
Neurology, Queen Square, London to evaluate the
effects of 12 months exposure to exenatide on the
motor and cognitive deficits of patients with PD (Clin-
ical trials.gov Identifier NCT01174810). Forty five
patients with moderate severity PD were randomized
to either self-administer exenatide in addition to their
regular PD medications or to acts as controls, i.e.
receive their conventional PD treatment only. Detailed
assessments were performed to quantify the effects of
12 months exposure to exenatide followed by repeat
assessment after a 2 month washout period. Results
of these assessments at 12 and 14 months have been
previously reported, potentially indicating advantages
among patients exposed to exenatide compared to con-
trols on both motor outcomes (Blinded video rating of
the Movement Disorders Society Unified Parkinson’s
Disease Rating Scale MDS-UPDRS and timed tests)
and non motor outcomes (Mattis Dementia Rating
Scale (DRS-2)) [10]. In parallel, patients randomised to
exenatide also experienced weight loss and an increase
in dyskinesias that necessitated lowering of their
Levodopa equivalent dose (LED).
The current manuscript adds to these data by
describing the results of detailed motor and non motor
assessments collected at 24 months post baseline
assessment, i.e. 12 months after cessation of the trial
drug to explore whether 1) any of the differences previ-
ously observed at 12 and 14 months had persisted and
2) and whether any confounding factors such as weight
loss, or minor baseline differences in disease severity
might contribute to these observed differences.
METHODS
Patients
The trial methods have been described in detail pre-
viously [10]. In brief, patients with moderate severity
PD meeting trial inclusion and exclusion criteria were
randomised into 2 groups; 1) to self administer exe-
natide by subcutaneous injection twice daily for 12
months in addition to their conventional PD medi-
cation or 2) to continue conventional PD medication
only. Detailed motor assessments were performed in
the practically defined “Off” medication state, and
repeated in the “On” medication state together with
a battery of non-motor scales at Baseline, 6, 12 and
14 months. All patients were then invited to have a
repeat assessment at 24 months post baseline visit, i.e.
12 months after cessation of exenatide, using the same
battery of validated motor and non motor scales. Ahead
of their final trial visit, patients were sent the PDQ39,
Smell identification test, Non Motor Symptoms (NMS)
Questionnaire, SCOPA Aut, and SCOPA sleep ques-
tionnaire to self-complete and bring to the clinic. On
the day of the visit, all patients withheld all con-
ventional PD medications overnight, and had a video
recording of the assessment of their MDS-UPDRS part
3 motor score, performed timed motor tests and then
took their regular PD medication. The patients were
then asked to complete MDS UPDRS part 1, 2, 4,
and when they confirmed that their best “On” state
was achieved, they had a further video of UPDRS part
3 motor score. During their “On” phase, the Dysk-
inesia rating scale, Montgomery Asberg Depression
Rating scale (MADRS), and Mattis DRS-2 were com-
pleted. Clinical observations (weight, pulse and blood
pressure) and any adverse events occurring during the
previous year were systematically recorded. Oral Glu-
cose tolerance test was performed at the 24 month
follow up visit as an indirect measure of insulin resis-
tance during the “off” phase.
Blinded video rating
To avoid the possibility of investigator bias, the
videos of the MDS-UPDRS part 3 motor scale were
rated by PD clinicians, trained and certified in MDS-
UPDRS scoring, and blinded to patient treatment
status. It is however impossible to rate “rigidity”
on video therefore for the MDS-UPDRS part 3, the
blinded scores are presented 1) excluding rigidity, and
also 2) with the addition of the open label rigidity
scores.
Analyses
All data are presented to enable comparisons in
mean scores at baseline and at 24 months together
with the interval change according to randomised
treatment allocation. The primary outcome was the
MDS-UPDRS Part 3 motor subscore in the practically
defined “Off” medication state. Secondary outcomes
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were; MDS-UPDRS part 3 motor subscore “On” med-
ication, MDS-UPDRS part 1, 2, and 4, Dyskinesia
rating Scale, timed motor tests, Levodopa Equivalent
Dose (LED), PDQ39, MATTIS DRS-2, MADRAS,
NMS Quest, SCOPA Sleep, and SCOPA AUT. All data
are presented on an “intention to treat” basis including
all patients who completed at least one follow up
assessment.
Two sided t tests were performed to compare
changes in scores from baseline to follow-up between
treated and untreated groups, and p values presented.
Further explorations whether there was any relation-
ship between observed treatment effects and possible
confounding factors such as weight loss, or biases such
as disease duration, and age at onset of disease at
baseline, were performed using Pearson’s correlations.
Data were analysed using IBM SPSS Statistics 20.
Patients who had undergone DBS
In total, three of the patients followed up at 24
months, had clinically deteriorated and had needed
Deep Brain Stimulation for the treatment of the PD
symptoms between the 12 and 24 month follow up
assessments; 1 in the exenatide group, 16 months after
baseline assessment and 2 in the Control group (One
at 14 months and one at 16 months follow-up).
Patients undergoing DBS frequently have substan-
tial lowering of their conventional PD medication. This
can mean that assessments in the Off medication and
OFF stimulation setting can be associated with much
more profound severity of “OFF” symptoms and signs,
presumably because of the long duration response to
L-dopa replacement that is not seen in the “practically
defined “Off” state after a short overnight withdrawal
[18]. Therefore it was predicted that OFF-medication
assessments in these 3 patients would be a potential
source of bias (favouring the exenatide group) and not
comparable with previous ratings or with the rest of the
cohort. Similarly these patients’ On drug and ON stim-
ulation assessments would also be subject to a potential
bias. For this reason, the decision was taken to use
“last observation carried forward” (LOCF) for these
patients for their motor scores (UPDRS, Dyskinesia
rating Scale and Timed Tests) and L-dopa equiva-
lent dose (LED) at the 24 month assessment and thus
ensure as much available data as possible was used in
the analysis. To ensure transparency, statistical anal-
yses were nevertheless subsequently repeated for the
primary outcome measure, including blinded ratings
of off medication, off stimulation assessments at 24
months for these 3 patients.
RESULTS
Of the 45 patients who underwent the original ran-
domisation, 1 patient dropped out prior to first follow
up visit and was replaced as per protocol, and excluded
from subsequent analyses. Two further patients with-
drew from exenatide treatment: the first at 9 months
due to dysgeusia combined with subjective PD deteri-
oration, and the second at 10 months due to excessive
weight loss. These patients continued follow up assess-
ments and data collection as per protocol. All 44
patients that had completed at least 1 follow up visit
(exenatide group: n = 20, Control group: n = 24) com-
pleted the further assessment at 24 months.
Baseline differences
Despite randomisation, there were minor (non-
significant) differences at baseline between treated and
untreated groups. The exenatide group had an older
age at study enrolment 61.4 (6.0) years versus control
group 59.4 (8.4) years. Exenatide patients also had a
shorter disease 9.6 (3.4) years v control group 11.0
(5.9) years,
Blinded video rating of MDS-UPDRS part 3 “off
medication”
Patients allocated to the exenatide group had a mean
improvement at 24 months compared with baseline
of 1.1 points (SD, 5.9) on the MDS-UPDRS part 3
motor score, while controls had a mean decline of
4.5 points (SD, 5.3) (a difference of 5.6 points (95%
CI, 2.2–9.0; p = 0.002); Table 1 and Fig. 1B). Addi-
tion of open label rating of rigidity scores to the
blinded data equated to a decline of 0.5 points (SD,
7.3) in the exenatide group, compared with a decline
of 8.5 points (SD, 6.3) in the control group (differ-
ence, 8.0 points; 95% CI, 3.8–12.2; p < 0.001); (Table 1
and Fig. 1A). Repeat analysis of the MDS-UPDRS
part 3 motor score Off medication/ off stimulation
including data from the 3 patients who had undergone
DBS showed a persistent advantage for the exenatide
group (difference of 5.2 points; 95% CI, 1.0–9.1;
p < 0.01).
MDS UPDRS on medication subscores
Open label rating of MDS-UPDRS part 3 “on med-
ication” showed an improvement in “on medication”
scores in the exenatide group (mean improvement 0.9
points, SD (6.8)) at the 24-month visit compared to
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Table 1
Change in the scores on MDS-UPDRS, LED, DRS and timed walking test at 24 month. A. Blinded rating excluding open label rigidity scores
in Off medication condition. B. Open label rating including rigidity scores in On medication condition
Baseline 24 months Difference baseline P
mean (SD) mean (SD) to 24 months value
mean (SD); 95% CI
Blinded-MDS UPDRS Part III. A “off medication”
Exenatide 31.0 (11.2) 29.8 (9.8) −1.1 (5.9); −3.9, 1.6 P = 0.002
Conventional PD medication 34.0 (16.1) 38.5 (15.1) 4.6 (5.3); 2.2, 6.7
MDS UPDRS Part III. B “on medication”
Exenatide 23.5 (6.3) 22.5 (7.2) −0.9 (6.9); −4.2, 2.3 P < 0.001
Conventional PD medication 25.3 (10.7) 33.2 (11.4) 7.8 (6.7); 5.0, 10.7
MDS-UPDRS Part I
Exenatide 10.4 (4.1) 12.4 (5.0) 2.0 (4.2); 0.0, 4.0 P = 0.049
Conventional PD medication 11.6 (4.7) 16.7 (8.2) 5.1 (5.5); 2.8, 7.4
MDS-UPDRS Part II
Exenatide 10.2 (5.2) 12.9 (7.1) 2.7 (5.4); 0.2, 5.3 P = 0.009
Conventional PD medication 12.9 (6.2) 19.9 (7.2) 7.0 (5.0); 4.9, 9.1
MDS-UPDRS Part IV
Exenatide 6.3 (2.4) 5.9 (3.4) −0.3 (2.6); −1.6, 09 P = 0.107
Conventional PD medication 6.3 (3.4) 7.3 (3.5) 1.0 (2.8); −0.1, 2.2
LED
Exenatide 973 (454) 1104.6 (506.5) 131.9 (192.3); 41.9, 221.9 P = 0.308
Conventional PD medication 977 (493) 1189.1 (679.5) 211.9 (298.7); 85.8, 338.1
Dyskinesia rating scale (on medication)
Exenatide 2.3 (2.8) 3.5 (4.2) 0.8 (6.0); −2.0, 3.6 P = 0.328
Conventional PD medication 2.6 (2.9) 2.0 (2.5) −0.6 (3.0); −1.8, 0.7
Timed walk “off medication”
Exenatide 17.3 (5.2) 17.1 (7.1) −0.2 (6.6); −3.2, 2.9 P = 0.85
Conventional PD medication 23.8 (22.4) 23.1 (19.0) −0.9 (15.8); −7.5, 5.8
Timed walk “on medication”
Exenatide 13.9 (3.1) 14.4 (3.4) 0.5 (5.0); −1.8, 2.8 P = 0.213
Conventional PD medication 13.7 (4.4) 16.7 (10.0) 3.4 (9.3); −0.5, 7.4
baseline. In contrast, individuals in the conventional
PD medication group deteriorated over the 24-month
trial period by 7.8 points SD (6.7). Both groups had
a decline in the MDS UPDRS part 1 and 2 sub-
scores although this was more modest in patients
previously treated with exenatide compared with con-
trols. There was no clear difference between groups
for MDS-UPDRS part IV, LED or Dyskinesia Rating
Scale (Table 1). The group randomised to Exenatide
had a smaller increase in LED than the group ran-
domised to be controls over the 24 month follow up
period.
Timed tasks
No significant differences were found in the timed
walk test ON or OFF medication (Table 1). While
there were sustained improvements in the number of
hand taps that could be performed with either hand
in both On and Off medication state in patients that
had received exenatide, only the number of hand taps
for the Left hand in the on medication state achieved
conventional threshold for significance (p = 0.026).
Mattis DRS-2
At 24 months patients in the exenatide group showed
a mean improvement in the Mattis DRS-2 of 1.8 points
compared with deterioration by mean of 3.5 points in
the control patients (difference, 5.3 points; 95% CI,
9.3–1.4; p = 0.006) (Fig. 2).
Montgomery asberg depression rating scale
At 24 months there was a mean improvement on the
MADRS of 1.9 points in the exenatide group SD (5.2),
and a mean deterioration in the control group of 1.5
points, SD (7.0) although this difference of 3.4 points
failed to reach statistical significance (Table 2).
PDQ39
While the scores favoured the exenatide patients in
both motor and non-motor measures listed above, there
was no improvement in the overall PDQ39 summary
index in the exenatide patients, nor in the compari-
son between the 2 groups at 24 months (Table 2).
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a
b
Fig. 1. A. Mean values of the MDS-UPDRS part 3 score by study
visit. (Data represent mean ± SEM). B. Change in MDS-UPDRS
part III Off medication by study visit (mean ± SEM).
Inspection of the PDQ39 subdomains reveals sub-
stantial variability between treatment groups even at
baseline.
Non motor symptoms questionnaires
Patients randomised to exenatide showed mean
improvements in NMS Quest, in night-time and overall
sleep quality while control patients deteriorated on
all these measures, although none of these measures
reached statistical significance (Table 2).
Adverse events
Patients allocated to the exenatide group had experi-
enced weight loss when measured at 12 and 14 months
(a recognised side effect of exenatide). At the 24 month
assessment, exenatide patients had a mean weight loss
Fig. 2. Change from baseline in the Mattis DRS-2 score by study
visit. Data represent mean ± SEM.
compared to baseline of 1.6 Kg SD(3.1), while con-
trols had a mean weight loss of 1.7 kg SD(5.8), with a
difference of 0.1 points (95% CI, 3.0–2.8; p = 0.93).
Oral glucose tolerance test
There was no difference in glucose tolerance
between the exenatide and control groups; In the
exenatide group the mean (SD) fasting glucose was 5.0
(0.5) mmol/L. The mean glucose level 2 hours later was
5.6 (1.4) mmol/L. While one patient met the threshold
for glucose intolerance (>7.7 mmol/L), no patients met
criteria for Diabetes mellitus. In the control group the
mean (SD) fasting glucose was 5.2 (1.5) mmol/L, and
2 hours later was 5.6 (1.3) mmol/L.
Correlations of clinical outcomes with baseline
variables
The change in MDS UPDRS part 3 between baseline
and 24 months was not significantly correlated with age
at PD onset, nor age at the start of the trial. Furthermore
there was no significant correlation between change in
MDS UPDRS part 3 and change in weight at 12, 14
or 24 month timepoints. There were no correlations
between changes in Mattis DRS-2 and age at onset of
the trial, nor age at symptoms onset.
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Table 2
Change in the score on Mattis-DRS2, MADRAS, PDQ39-SI, NMS Quest, SCOPA Sleep and SCOPA AUT
Baseline 24 months Difference baseline P
mean (SD) mean (SD) to 24 months value
mean (SD); 95% CI
Mattis DRS-2
Exenatide 140.1 (7.7) 141.9 (3.1) 1.8 (65); −1.2, 4.8 P = 0.006
Conventional PD medication 139.5 (4.5) 135.9 (7.3) −3.5 (6.4); −0.8, −6.3
MADRAS
Exenatide 10.9 (5.1) 9.0 (4.6) −1.9 (5.2); 0.5, −4.3 P = 0.79
Conventional PD medication 11.0 (5.4) 12.5 (8.6) 1.5 (7.0); −1.4, 4.4
PDQ39 summary index
Exenatide 19.2 (13.5) 19.1 (13.5) −0.1 (12.3); −5.9, 5.6 P = 0.682
Conventional PD medication 24.5 (12.8) 25.7 (16.5) 1.2 (9.3); −2.7, 5.1
NMS Quest
Exenatide 10.4 (3.6) 9.6 (4.7) −0.8 (3.8); −2.6, 1.0 P = 0.403
Conventional PD medication 10.5 (5.5) 10.7 (6.0) 0.2 (4.3); −1.6, 2.1
SCOPA Sleep night time
Exenatide 6.3 (3.6) 5.4 (3.0) −0.9 (2.8); −2.2, 04 P = 0.278
Conventional PD medication 5.6 (3.5) 5.7 (4.3) 0.1 (3.3); −1.3, 1.5
SCOPA Sleep day time
Exenatide 4.1 (3.5) 4.9 (4.0) 0.7 (1.9); −0.2, 1.6 P = 0.658
Conventional PD medication 4.3 (2.7) 4.7 (2.7) 0.4 (2.3); −0.5, 1.4
SCOPA AUT
Exenatide 11.7 (5.8) 12.7 (4.3) 1.0 (5.1); −1.4, 3.4 P = 0.750
Conventional PD medication 12.7 (6.7) 13.2 (8.3) 0.4 (5.9); −2.0, 3.0
DISCUSSION
In this open label, proof of concept trial, we have
observed multiple differences in clinical outcome mea-
sures between patient groups according to treatment
allocation, that have persisted for 24 months (ie 12
months after cessation of exenatide injections). The
absolute magnitude of the difference observed is of
potential clinical relevance. Inclusion of the rigidity
scoring made by the unblinded investigator equated to
an 8.0 points difference in MDS-UPDRS part 3 score
at 24 months. Adding the blinded video rating of MDS-
UPDS part 3 to the differences seen in parts 1, 2, and 4
of the scale equated to a 14.5 point advantage in favour
of exenatide at 24 months. This was accompanied by
effects seen across a range of other measures; Mattis
DRS-2, MADRS, Timed tests, LED and Dyskinesia
rating scale. However, due to the open label design
of the trial it remains impossible to establish without
doubt, if the nature of this effect is real, entirely placebo
driven or a combination of the two.
The decision to extend the follow up for a further 12
months was taken to allow inevitable placebo effects
at trial onset, to at least begin to diminish. While we
are unaware of previous reports of placebo effects last-
ing 24 months, the continued existence of a placebo
driven effect cannot be ruled out. Nevertheless, these
data were collected in a highly cost efficient manner
and this type of trial design has thus been the subject
for discussion as a possible means of gaining prelimi-
nary supportive evidence of clinical safety and efficacy
ahead of the major financial investment necessary for
formal double blind evaluations of clinical efficacy
[11].
The additional data collected have also been used to
explore whether there are any other explanations for
the observed persisting differences. In any randomised
trial, chance differences between groups can be present
at baseline despite randomisation. This is more likely
in trials with small numbers of patients, and such dif-
ferences can be an important source of confounding.
In this trial, minor differences in age at onset and dis-
ease duration were observed. On one hand older age
of onset has been associated with more rapid progres-
sion [12] but on the other hand it has been proposed
that the rate of progression in early PD is faster than in
later disease [13–15]. Either way, we did not identify
any positive correlation between age at onset, disease
duration and change in either the MDS UPDRS or the
Mattis DRS-2 to suggest that differences observed may
have been explicable by these potential confounders.
Of note is the observed discrepancy between the
improvement in some of the motor and non-motor
scales and the lack of improvement in PDQ39 Sum-
mary Index. Exploring this further revealed quite
marked differences between some of the PDQ39 sub-
domains comparing exenatide patients with controls at
baseline. This is likely an example of how, despite the
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randomisation process, differences at baseline, partic-
ularly in the subdomains of scales can occur, and it
is likely that these baseline differences may impact
on observed differences emerging over the subsequent
2 years. It is envisaged that future trials with larger
numbers of participants will be less vulnerable to dif-
ferences in baseline scale scores.
The adverse events at 24 months are well in keep-
ing with what would be expected in moderate severity
PD patients and the known side effects of exenatide.
Weight loss was reversible upon stopping exenatide
injections, and there was no difference in the change
in body mass index at 24 months between patients in
exenatide and control groups. No correlation was found
between the change in part 3 MDS UPDRS at 12, 14
and 24 months and weight loss, making it less likely
that exenatide patients had improved motor scores as
a result of their BMI being reduced during the first 12
month trial period. Our exenatide group of patients fre-
quently described gastrointestinal symptoms, in keep-
ing with the known adverse event profile of exenatide.
We did not find evidence in our data to suggest
that glucose tolerance is different in PD patients who
received Exenatide for 12 months in addition to best
medical therapy. Based on these results, we find lit-
tle to suggest that any biological effects of exenatide
in PD are solely related to improvement in periph-
eral glucose metabolic control. Central mechanisms of
glucose sensing and insulin signalling warrant further
explorations.
Reassuringly, the increase in Dyskinesia Rating
Scale scores necessitating the reduction in LED seen at
12 and 14 months in the exenatide group were no longer
significantly different from controls at 24 months. Four
patients in the exenatide group who had worsening of
peak dose dyskinesia at 12 and 14 months that neces-
sitated lowering the LED, subsequently had their LED
re- increased by the 24 month visit. Although not reach-
ing significance, exenatide patients still had slightly
more dyskinesias than controls despite lower increases
in LED overall, therefore it remains possible that exe-
natide may exacerbate dyskinesia particularly during
the period of exposure.
To date, the design of trials of putative disease mod-
ifying agents has focused on the demonstration of
sustained effects on motor function [16]. However it
has been proposed that identifying effects which delay
the development of major milestones such as demen-
tia, would be a more useful approach [17]. In our trial,
cognitive decline was measured with Mattis DRS-2
scale during the on medication state at every time
point. There was divergence in cognitive performance
between the groups, with a 5-point advantage in the
Mattis DRS-2 at 12 months that persisted as a 6.3-point
advantage at 14 months and 5.3-points at 24 months.
No correlations were found between age at PD onset
and Mattis DRS-2 at baseline nor between change in
Mattis DRS-2 at 12, 14 or 24 months.
In conclusion, aside from the changes in MDS-
UPDRS scores, there was also persistent divergence in
cognitive performance between the groups, with sig-
nificant differences which were sustained along the
trial period, far beyond the 12 month period of drug
exposure. These data provide continued support for
formal double blind trials of GLP-1 agonists as disease
modifying drugs in PD.
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